18 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
29 Jul 21
Oncorus Expands its Board with Appointment of Barbara Yanni
4:31pm
our mission of realizing the full promise of viral immunotherapies for cancer patients,” said Theodore (Ted) Ashburn, M.D., Ph.D., President and CEO … science, pipeline diversification, a comprehensive manufacturing strategy, and a mission-driven mindset,” said Ms. Yanni. “I’m thrilled to join Oncorus
8-K
EX-99.1
ONCR
Oncorus, Inc.
14 Dec 20
Oncorus Appoints Scott Canute to its Board of Directors
9:03am
progression and patient-centric mission.”
Mr. Canute previously served as President of Global Manufacturing and Corporate Operations at Genzyme from 2010
8-K
EX-99.1
ONCR
Oncorus, Inc.
4 Jan 21
Entry into a Material Definitive Agreement
4:12pm
a central role in enabling us to advance our mission to realize the full promise of viral immunotherapy for cancer patients. Operational
8-K
EX-99.1
ONCR
Oncorus, Inc.
22 May 23
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
4:13pm
(Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Our exceptional team continues to drive our mission of realizing the full
8-K
EX-99.1
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
and reiterating guidance for its cash runway into early 2024.
“Oncorus’ mission is now focused on realizing the full promise of IV-administered, self-amplifying
8-K
EX-99.1
0w8edc 5ov7
12 Nov 20
Oncorus Reports Third Quarter 2020 Financial Results and Provides Business Highlights
7:00am
8-K
EX-99.1
ztesginsewetw0u sirr
10 Mar 21
Oncorus Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
7:15am
8-K
EX-99.1
rec1d2nuhr
10 Jan 22
Regulation FD Disclosure
8:17am
DRS/A
amnf9zgzj2
20 Dec 19
Draft registration statement (amended)
12:00am
424B4
6cjtgz6s9 semjb4
12 Feb 21
Prospectus supplement with pricing info
4:23pm
S-1
43vrx21g 2oszp
11 Sep 20
IPO registration
4:49pm
DRS/A
uwtopp45s2vo2bdax759
26 Aug 20
Draft registration statement (amended)
12:00am
DRS
5mrrq29a bs9q
31 Oct 19
Draft registration statement
12:00am
DRS/A
k1sf no9oy2dsnwy0b0x
29 Jul 20
Draft registration statement (amended)
12:00am
424B4
78rhqj
2 Oct 20
Prospectus supplement with pricing info
12:00am
DRS
jrc6ik3ttxnbp1465
28 Jan 21
Draft registration statement
12:00am
- Prev
- 1
- Next